The risk and severity of developing symptomatic palpitations when prescribed mirabegron for overactive bladder

European Journal of Obstetrics, Gynecology, and Reproductive Biology
Aswini Balachandran, Jonathan Duckett

Abstract

Mirabegron is a new selective β3-adrenoreceptor agonist licensed for the treatment of overactive bladder (OAB). In clinical trials, mirabegron is well-tolerated with a low side-effect profile. There is little data available on the risks in a non-selected population. The presence of β-adrenoreceptors in cardiac and vascular tissue leads to the possibility of the development of adverse cardiovascular events. We conducted a consecutive cohort study to assess the risk of developing palpitations, the severity of the condition and to investigate any underlying risk factors that predispose patients with OAB to develop palpitations whilst taking mirabegron. A consecutive cohort of patients with OAB was studied between February 2013 and June 2014. Patients were prescribed mirabegron 50mg daily and outcomes assessed at 6 weeks. Patients with known cardiac arrhythmias were excluded. In patients who developed palpitations, a detailed account of their symptoms and medical history were documented and a 12-lead electrocardiogram (ECG) was performed to assess heart rate, QT interval and the presence of any persisting arrhythmia was conducted. A total of 279 patients were started on mirabegron. Eight patients (2.9%) reported palpitations whilst...Continue Reading

References

Oct 20, 2012·The Journal of Urology·Victor W NittiSender Herschorn
Feb 21, 2013·Neurourology and Urodynamics·Christopher R ChappleUNKNOWN BLOSSOM Investigator Group
Mar 9, 2013·International Urogynecology Journal·Christopher R ChappleUNKNOWN Dragon Investigator Group
May 3, 2013·Therapeutics and Clinical Risk Management·Karl-Erik Andersson
Oct 16, 2013·Neurourology and Urodynamics·Christopher R ChappleMartin C Michel
Jun 7, 2014·BMJ : British Medical Journal·Peter DoshiSusan dosReis

❮ Previous
Next ❯

Citations

Jan 25, 2016·International Urogynecology Journal·Jonathan Duckett, Aswini Balachandran
Mar 17, 2016·Expert Opinion on Drug Safety·Dudley RobinsonLinda Cardozo
Jun 19, 2016·European Journal of Obstetrics, Gynecology, and Reproductive Biology·Helena Kopp KallnerDaniel Altman
Jul 12, 2017·Nature Reviews. Urology·Karl-Erik Andersson
Apr 26, 2020·The Journal of Pharmacology and Experimental Therapeutics·Hiroya MizutaniEiji Sasaki
Sep 13, 2018·Journal of Clinical Medicine·Pawel MiotlaTomasz Rechberger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.